Skip to main content
Premium Trial:

Request an Annual Quote

IDS, Biosignatures Set License Agreement

NEW YORK (GenomeWeb News) – Immunodiagnostic Systems has licensed the right to use new biomarkers developed by Biosignatures for use in immunoassay diagnostic test kits for kidney diseases, IDS said today.

The agreement covers the proteomics-based biomarker technology developed by Biosignatures, a Newcastle, UK-based company that spun out from Nonlinear Dynamics. The initial focus of the license agreement will cover kidney diseases and related conditions and will use the IDS iSYS platform, IDS said.

IDS CEO Roger Duggan said in a statement that Biosignatures has "an enlightened approach to proteomics based upon extensive hard-headed commercial experience."

Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.